Similar articles

• Treatment step down should be avoided at entry in COPD therapeutic trials.

  Marchand E. Marchand E. Am J Respir Crit Care Med. 2008 Jul 1;178(1):105-6; author reply 106-7. doi: 10.1164/ajrccm.178.1.105a. Am J Respir Crit Care Med. 2008. PMID: 18565962 No abstract available.
• Do we need three players in COPD treatment?

  Maestrelli P, Mason P, Costa F, Paggiaro P. Maestrelli P, et al. Respiration. 2013;86(4):275-6. doi: 10.1159/000353553. Epub 2013 Aug 28. Respiration. 2013. PMID: 23988429 No abstract available.
• Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

  Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Aaron SD, et al. Ann Intern Med. 2007 Apr 17;146(8):545-55. doi: 10.7326/0003-4819-146-8-200704170-00152. Epub 2007 Feb 19. Ann Intern Med. 2007. PMID: 17310045 Clinical Trial.
• Tiotropium for chronic obstructive pulmonary disease.

  [No authors listed] [No authors listed] Drug Ther Bull. 2003 Feb;41(2):15-6. doi: 10.1136/dtb.2003.41215. Drug Ther Bull. 2003. PMID: 12630336 Review.
• Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

  Keating GM, McCormack PL. Keating GM, et al. Drugs. 2007;67(16):2383-405. doi: 10.2165/00003495-200767160-00006. Drugs. 2007. PMID: 17983257 Review.